Blocks 26S proteasome activity by inhibiting the ubiquitin C-terminal hydrolase 5 (UCHL5) and ubiquitin-specific peptidase 14 (USP14) activities of the 19S regulatory subunit without affecting the catalytic activity of the 20S core subunit. b-AP15 displays several differences to bortezomib including insensitivity to over-expression of the anti-apoptotic mediator Bcl-2 and anti-tumor activity in four solid tumor models.
|Purity||>98% (TLC), NMR (conforms)|
|Quantity||5 mg, 25 mg|
|Molecular Weight||419.4 Da|
|Physical State||Pale yellow powder|
|Solubility||DMSO (35 mg/mL)|
|Storage||4°C, (-20°C Long term). The product can be shipped at room temperature.|